Recombinant Interferon in Advanced Breast Cancer
Author Information
Author(s): A. Nethersell, H. Smedley, M. Katrak, T. Wheeler, K. Sikora
Primary Institution: Ludwig Institute for Cancer Research, Department of Radiotherapy, Addenbrooke's Hospital, Cambridge
Hypothesis
Can recombinant leucocyte interferon (rIFN-aA) be effective in treating advanced breast cancer?
Conclusion
The study found that while some patients showed initial tumor regression, the overall response rate was low and significant toxicity was observed.
Supporting Evidence
- Nine patients showed some evidence of tumor regression at 4 weeks.
- Only two patients continued to respond at 12 weeks.
- Four patients died during treatment, with two deaths possibly related to the therapy.
Takeaway
Doctors gave a special medicine to 15 women with serious breast cancer to see if it would help, but many had bad side effects and only a few got better.
Methodology
Fifteen patients with advanced breast cancer were treated with recombinant interferon for up to 12 weeks, with assessments of tumor response and side effects.
Limitations
The study was stopped early due to poor response rates and significant toxicity.
Participant Demographics
All participants were postmenopausal women aged 41 to 69, with a history of previous cancer treatments.
Want to read the original?
Access the complete publication on the publisher's website